Lisata Therapeutics, Inc. (LSTA)

NCM – Real vaqt narxi. Valyuta: USD

3.26

0.00 (0.00%)

Yopilishda: May 12, 2026, 4:00 PM EDT

04.05.2026

Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

09.03.2026

Lisata Therapeutics to be acquired by Kuva Labs

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), a clinical-stage pharmaceutical company developing therapies to treat advanced solid tumors and other serious diseases, announced that it has agreed to be acquired by privately held Kuva Labs. Under the terms of a definitive agreement, Kuva will launch a tender offer to purchase all outstanding Lisata shares for $5 per share in cash at closing, plus one contingent value right (CVR) per share.

09.03.2026

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE, March 9, 2026 /PRNewswire/ -- Ademi LLP is investigating Lisata (NASDAQ: LSTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Kuva Labs Inc. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.

06.03.2026

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share

27.01.2026

Lisata regains China rights to pancreatic cancer drug

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said it has mutually terminated a licensing and collaboration agreement with China's Qilu Pharmaceutical, regaining full rights to its cancer drug candidate certepetide in the Greater China region. The February 2021 agreement granted Qilu exclusive rights to develop and commercialize certepetide in Mainland China, Hong Kong, Macau and Taiwan.

27.01.2026

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

Lisata regains full development rights to certepetide in the Greater China Region Lisata regains full development rights to certepetide in the Greater China Region

21.01.2026

LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Lisata Therapeutics, Inc. (NASDAQ: LSTA) to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable contingent value rights payable under certain conditions is fair to Lisata shareholders. Halper Sadeh encourages Lisata shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersade.

Videolar

No Data

There is no data to display

Press-relizlar

04.05.2026

Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

09.03.2026

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

06.03.2026

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share

27.01.2026

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

Lisata regains full development rights to certepetide in the Greater China Region Lisata regains full development rights to certepetide in the Greater China Region

Lisata Therapeutics, Inc. (LSTA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Lisata Therapeutics, Inc. (LSTA)

Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders

Lisata Therapeutics to be acquired by Kuva Labs

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

Lisata regains China rights to pancreatic cancer drug

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders

Videolar

No Data

Press-relizlar

Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders

Lisata Therapeutics to be acquired by Kuva Labs

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

Lisata regains China rights to pancreatic cancer drug

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders

Videolar

No Data

Press-relizlar

Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

Search stocks

Lisata Therapeutics, Inc. (LSTA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Lisata Therapeutics, Inc. (LSTA)

Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders

Lisata Therapeutics to be acquired by Kuva Labs

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

Lisata regains China rights to pancreatic cancer drug

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders

Videolar

No Data

Press-relizlar

Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders

Lisata Therapeutics to be acquired by Kuva Labs

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

Lisata regains China rights to pancreatic cancer drug

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders

Videolar

No Data

Press-relizlar

Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide